These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. A Phase 2, Randomized, Active-controlled, Observer-blinded Study to Assess the Immunogenicity, Tolerability and Safety of Bivalent rLP2086, a Meningococcal Serogroup B Vaccine, Coadministered With Tetanus, Diphtheria and Acellular Pertussis Vaccine and Serogroup A, C, Y and W-135 Meningococcal Conjugate Vaccine in Healthy US Adolescents. Muse D; Christensen S; Bhuyan P; Absalon J; Eiden JJ; Jones TR; York LJ; Jansen KU; O'Neill RE; Harris SL; Perez JL Pediatr Infect Dis J; 2016 Jun; 35(6):673-82. PubMed ID: 26974889 [TBL] [Abstract][Full Text] [Related]
9. Immunogenicity, Safety, and Tolerability of Bivalent rLP2086 Meningococcal Group B Vaccine Administered Concomitantly With Diphtheria, Tetanus, and Acellular Pertussis and Inactivated Poliomyelitis Vaccines to Healthy Adolescents. Vesikari T; Wysocki J; Beeslaar J; Eiden J; Jiang Q; Jansen KU; Jones TR; Harris SL; O'Neill RE; York LJ; Perez JL J Pediatric Infect Dis Soc; 2016 Jun; 5(2):180-7. PubMed ID: 26803328 [TBL] [Abstract][Full Text] [Related]
10. A randomized, phase 1/2 trial of the safety, tolerability, and immunogenicity of bivalent rLP2086 meningococcal B vaccine in healthy infants. Martinon-Torres F; Gimenez-Sanchez F; Bernaola-Iturbe E; Diez-Domingo J; Jiang Q; Perez JL Vaccine; 2014 Sep; 32(40):5206-11. PubMed ID: 25077420 [TBL] [Abstract][Full Text] [Related]
11. A phase 2 open-label safety and immunogenicity study of a meningococcal B bivalent rLP2086 vaccine in healthy adults. Marshall HS; Richmond PC; Nissen MD; Wouters A; Baber J; Jiang Q; Anderson AS; Jones TR; Harris SL; Jansen KU; Perez JL Vaccine; 2013 Mar; 31(12):1569-75. PubMed ID: 23352429 [TBL] [Abstract][Full Text] [Related]
12. Bivalent rLP2086 Vaccine (Trumenba(®)): A Review in Active Immunization Against Invasive Meningococcal Group B Disease in Individuals Aged 10-25 Years. Shirley M; Dhillon S BioDrugs; 2015 Oct; 29(5):353-61. PubMed ID: 26394633 [TBL] [Abstract][Full Text] [Related]
13. Neisseria meningitidis Serogroup B Vaccine, Bivalent rLP2086, Induces Broad Serum Bactericidal Activity Against Diverse Invasive Disease Strains Including Outbreak Strains. Harris SL; Donald RG; Hawkins JC; Tan C; O'Neill R; McNeil LK; Perez JL; Anderson AS; Jansen KU; Jones TR Pediatr Infect Dis J; 2017 Feb; 36(2):216-223. PubMed ID: 27846061 [TBL] [Abstract][Full Text] [Related]
14. Persistence and 4-year boosting of the bactericidal response elicited by two- and three-dose schedules of MenB-FHbp: A phase 3 extension study in adolescents. Vesikari T; Østergaard L; Beeslaar J; Absalon J; Eiden JJ; Jansen KU; Jones TR; Harris SL; Maansson R; Munson S; O'Neill RE; York LJ; Perez JL Vaccine; 2019 Mar; 37(12):1710-1719. PubMed ID: 30770221 [TBL] [Abstract][Full Text] [Related]
15. Bactericidal activity of sera from adolescents vaccinated with bivalent rLP2086 against meningococcal serogroup B outbreak strains from France. Taha MK; Hawkins JC; Liberator P; Deghmane AE; Andrew L; Hao L; Jones TR; McNeil LK; O'Neill RE; Perez JL; Jansen KU; Anderson AS Vaccine; 2017 Mar; 35(11):1530-1537. PubMed ID: 28196734 [TBL] [Abstract][Full Text] [Related]
16. Immunogenicity, safety, and tolerability of the meningococcal serogroup B bivalent rLP2086 vaccine in adult laboratory workers. Reiner DM; Bhuyan P; Eiden JJ; Ginis J; Harris S; Jansen KU; Jiang Q; Jones TR; O'Neill RE; York LJ; Perez JL Vaccine; 2016 Feb; 34(6):809-13. PubMed ID: 26707218 [TBL] [Abstract][Full Text] [Related]
17. Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: a randomised, single-blind, placebo-controlled, phase 2 trial. Richmond PC; Marshall HS; Nissen MD; Jiang Q; Jansen KU; Garcés-Sánchez M; Martinón-Torres F; Beeslaar J; Szenborn L; Wysocki J; Eiden J; Harris SL; Jones TR; Perez JL; Lancet Infect Dis; 2012 Aug; 12(8):597-607. PubMed ID: 22569484 [TBL] [Abstract][Full Text] [Related]
18. A review of the immunogenicity, safety and current recommendations for the meningococcal serogroup B vaccine, MenB-FHbp. Burman C; Alderfer J; Snow VT J Clin Pharm Ther; 2020 Apr; 45(2):270-281. PubMed ID: 31820483 [TBL] [Abstract][Full Text] [Related]
19. Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled study. Santolaya ME; O'Ryan ML; Valenzuela MT; Prado V; Vergara R; Muñoz A; Toneatto D; Graña G; Wang H; Clemens R; Dull PM; Lancet; 2012 Feb; 379(9816):617-24. PubMed ID: 22260988 [TBL] [Abstract][Full Text] [Related]
20. Characteristics of a new meningococcal serogroup B vaccine, bivalent rLP2086 (MenB-FHbp; Trumenba®). Gandhi A; Balmer P; York LJ Postgrad Med; 2016 Aug; 128(6):548-56. PubMed ID: 27467048 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]